Citations

Clear

3314 citation(s) found for "Yu, Alexander".

QS5: The Effect of Stem Cells and Local Tacrolimus on Neurite Extension
Saffari, Tiam M. , Chan, Katelyn, Saffari, Sara , Chan, Katelyn, Borschel, Gregory Howard , Shin, Alexander Y.

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | July 27, 2021 | Volume: 9 | Issue: 7S | Pages: 19-19

10.1097/01.gox.0000770024.35327.48 Get It

Purpose: Application of mesenchymal stem cells (MSCs) or tacrolimus (FK506), an FDA approved immunosuppressant, to nerve grafts has been a topic of interest to enhance peripheral nerve regeneration. The aim of this study was to investigate the combined effect of MSCs and local delivery of FK506 on nerve regeneration when applied to nerve autografts and decellularized nerve allografts. Methods: A three-dimensional (3D) in vitro compartmented cell culture system, validated by Tajdaran et al (2019), consisted of rat neonatal dorsal root ganglion (DRG) adjacent to rat nerve autograft or decellularized allograft. This model was used to evaluate regenerating neurites from the DRG into the peripheral nerve scaffold. Nerve autografts and decellularized allografts were augmented with (i) dynamic undifferentiated MSC seeding, (ii) local application of FK506 (100 ng/mL) or (iii) both (N=9/group). Local application was ensured by isolating the central system (i.e. DRG side) from the peripheral system (i.e. nerve graft side), where treatment was applied. After 48-hours of incubation, DRG-nerve graft constructs were collected, fixed, sectioned and stained against neurofilament-160 to measure neurite extension. CD90 staining was used to confirm stem cell characterization. Results: All grafts treated with MSCs confirmed CD90 expression. Compared to untreated autografts, neurite extension in autografts treated with FK506 and autografts treated with MSCs and FK506 combined were found superior (P<0.001 and P=0.0001, respectively), and comparable to autografts treated with MSCs (P=0.12). Compared to untreated allografts, allografts treated with FK506, and allografts treated with MSCs and FK506 were found superior (P<0.001 and P=0.0001, respectively), and allografts treated with MSCs were found comparable (P=0.09). All autograft groups were found superior compared to their respective allograft treatment group (P<0.05). Solely allografts receiving combined treatment were found superior to untreated autografts (P<0.05). Conclusion: MSCs or FK506 treatment improved neurite outgrowth and when combined, this resulted in significant synergistic neurite extension in both autografts and allografts in comparable patterns. Schematic overview of 3D compartmented cell culture system for isolated evaluation of treatment with MSCs and local FK506 in vitro. A 3.5 mm autograft or allograft with or without undifferentiated MSC seeding is attached to a DRG. DRG-nerve graft constructs are placed through a silicone isolator in the middle of a 24-wells plate to isolate the DRG from the nerve graft. FK506 containing media was added to the nerve graft side.
Predictive modeling of spread in adult‐onset isolated dystonia: Key properties and effect of tremor inclusion
Wang, Meng , Morgante, Francesca , Adler, Charles H. , Bäumer, Tobias , Berardelli, Alfredo , Blumin, Joel H. , Borsche, Max , Brashear, Allison , Deik, Andres , Duque, Kevin R. , Feuerstein, Jeanne , Fox, Susan H. , LeDoux, Mark S. , Leegwater‐Kim, Julie, Mahajan, Abhimanyu , Ondo, William G. , Pantelyat, Alexander , Pirio‐Richardson, Sarah, Roze, Emmanuel , Saunders‐Pullman, Rachel , Suchowersky, Oksana , Truong, Daniel , Morgante, Francesca , Adler, C H , Berardelli, Alfredo , Borsche, Max , Mahajan, Abhimanyu , Martino, Davide , Pantelyat, Alex , Sajobi, Tolulope T. , Berman, Brian D. , Espay, Alberto J. , Ferrazzano, Gina , Frank, Samuel , Hallett, Mark , Jankovic, Joseph J. , Malaty, Irene A. , Vidailhet, Marie , Shukla, Aparna Wagle , Perlmutter, Joel S. , Jinnah, H. A.

Mayo Clinic

European Journal of Neurology | July 22, 2021 | Volume: 28 | Issue: 12 | Pages: 3999-4009

10.1111/ene.15031 | PMID 34296504 Get It

AbstractBackground and purposeSeveral clinical and demographic factors relate to anatomic spread of adult‐onset isolated dystonia, but a predictive model is still lacking. The aims of this study were: (i) to develop and validate a predictive model of anatomic spread of adult‐onset isolated dystonia; and (ii) to evaluate whether presence of tremor associated with dystonia influences model predictions of spread.MethodsAdult‐onset isolated dystonia participants with focal onset from the Dystonia Coalition Natural History Project database were included. We developed two prediction models, one with dystonia as sole disease manifestation (“dystonia‐only”) and one accepting dystonia OR tremor in any body part as disease manifestations (“dystonia OR tremor”). Demographic and clinical predictors were selected based on previous evidence, clinical plausibility of association with spread, or both. We used logistic regressions and evaluated model discrimination and calibration. Internal validation was carried out based on bootstrapping.ResultsBoth predictive models showed an area under the curve of 0.65 (95% confidence intervals 0.62–0.70 and 0.62–0.69, respectively) and good calibration after internal validation. In both models, onset of dystonia in body regions other than the neck, older age, depression and history of neck trauma were predictors of spread.ConclusionsThis predictive modeling of spread in adult‐onset isolated dystonia based on accessible predictors (demographic and clinical) can be easily implemented to inform individuals’ risk of spread. Because tremor did not influence prediction of spread, our results support the argument that tremor is a part of the dystonia syndrome, and not an independent or coincidental disorder.
Surgical Angiogenesis of Decellularized Nerve Allografts Improves Early Functional Recovery in a Rat Sciatic Nerve Defect Model
Saffari, Tiam M. , Mathot, Femke , Friedrich, Patricia F. , Bishop, Allen T. , Shin, Alexander Y.

Mayo Clinic

Plastic & Reconstructive Surgery | July 22, 2021 | Volume: 148 | Issue: 3 | Pages: 561-570

10.1097/prs.0000000000008291 | PMID 34292916 Get It

Background: Surgical angiogenesis applied to nerve grafts has been suggested to enhance nerve regeneration after nerve injury. The authors hypothesized that surgical angiogenesis to decellularized nerve allografts would improve functional recovery in a rat sciatic nerve defect model. Methods: Sixty Lewis rats were divided in three groups of 20 animals each. Unilateral sciatic nerve defects were repaired with (1) autografts, (2) decellularized allografts, and (3) decellularized allografts wrapped with a superficial inferior epigastric artery fascial flap to add surgical angiogenesis. Twelve and 16 weeks after surgery, nerve regeneration was assessed using functional, electrophysiologic, histologic, and immunofluorescence analyses. Ultrasonography was used during the survival period to noninvasively evaluate muscle atrophy and reinnervation by measuring cross-sectional muscle area. Results: Surgical angiogenesis of allografts demonstrated significantly improved isometric tetanic force recovery at 12 weeks, compared to allograft alone, which normalized between groups at 16 weeks. Cross-sectional muscle areas showed no differences between groups. Electrophysiology showed superiority of autografts at both time points. No differences were found in histologic analysis, besides a significantly inferior N ratio in allografts at 12 weeks. Immunofluorescent expression of CD34, indicating vascularity, was significantly enhanced in the superficial inferior epigastric artery fascial group compared to allografts at 12 weeks, with highest expression at 16 weeks compared to all groups. Conclusion: Surgical angiogenesis with an adipofascial flap to the nerve allograft increases vascularity in the nerve graft, with subsequent improvement of early muscle force recovery, comparable to autografts.
PRRX1–NCOA1‐rearranged fibroblastic tumour: a clinicopathological, immunohistochemical and molecular genetic study of six cases of a potentially under‐recognised, distinctive mesenchymal tumour
Dermawan, Josephine K. , Azzato, Elizabeth M. , Thangaiah, Judith Jebastin, Gjorgova‐Gjeorgievski, Sandra, Folpe, Andrew L. , Fritchie, Karen , Jebastin Thangaiah, Judith, Folpe, Andrew , Agaimy, Abbas , Dermawan, Josephine K T , Rubin, Brian P.

Mayo Clinic

Histopathology | July 17, 2021 | Volume: 79 | Issue: 6 | Pages: 997-1003

10.1111/his.14454 | PMID 34272753 Get It

AimsPRRX1–NCOA1‐rearranged fibroblastic tumour is a recently described, rare mesenchymal tumour. Only four cases have been previously reported. The aim of this article is to report six additional cases of this unusual mesenchymal neoplasm, with an emphasis on its differential diagnosis.Methods and resultsThe six cases were from three females and three males (age, 20–49 years; median, 42 years). Three tumours were located on the abdominal wall; two from the shoulder/axillary areas, and one on the lateral hip. All presented as slow‐growing subcutaneous nodules, ranging from 26 to 55 mm (median, 40 mm). The tumours consisted of circumscribed, variably cellular nodules composed of relatively bland plump spindled to epithelioid cells arranged singly, in cords, and occasionally in nests, embedded in hyalinised and collagenous stroma. Small hypocellular myxoid zones with ropey collagen fibres were present, as were irregularly dilated, gaping, crescent‐shaped or staghorn‐like thin‐walled vessels, best appreciated at the periphery. Immunohistochemistry for CD34, S100, MUC4 and STAT6 was consistently negative. RNA‐sequencing revealed PRRX1–NCOA1 fusions in all cases. Of the four cases with limited follow‐up (1.5–4 months), none recurred following local surgical excision.ConclusionsThe morphological features of PRRX1–NCOA1‐rearranged fibroblastic tumour overlap with those of RB1‐deficient soft‐tissue tumours, solitary fibrous tumour, and low‐grade fibromyxoid sarcoma/sclerosing epithelioid fibrosarcoma. This differential diagnosis can be resolved with a combination of careful morphological study and the application of a panel of immunostains, although molecular genetic study is most definitive. The natural history of PRRX1–NCOA1‐rearranged fibroblastic tumour appears to be quite favourable, although longer‐term study of a larger number of cases is warranted.
Full field-of-view, high-resolution, photon-counting detector CT: technical assessment and initial patient experience
Rajendran, Kishore , Petersilka, Martin, Henning, André , Shanblatt, Elisabeth R. , Marsh, Jeffrey F., Thorne, Jamison E. , Schmidt, Bernhard , Flohr, Thomas , Marsh, Jeffrey, Thorne, Jamison, Fletcher, Joel, McCollough, Cynthia, Rajendran, Kishore , Fletcher, Joel G. , McCollough, Cynthia H. , Leng, Shuai

Mayo Clinic

Physics in Medicine & Biology | July 16, 2021 | Volume: 66 | Issue: 20 | Pages: 205019

10.1088/1361-6560/ac155e | PMID 34271558 Get It

Abstract We report a comprehensive evaluation of a full field-of-view (FOV) photon-counting detector (PCD) computed tomography (CT) system using phantoms, and qualitatively assess image quality in patient examples. A whole-body PCD-CT system with 50 cm FOV, 5.76 cm z-detector coverage and two acquisition modes (standard: 144 × 0.4 mm collimation and ultra-high resolution (UHR): 120 × 0.2 mm collimation) was used in this study. Phantoms were scanned to assess image uniformity, CT number accuracy, noise power spectrum, spatial resolution, material decomposition and virtual monoenergetic imaging (VMI) performance. Four patients were scanned on the PCD-CT system with matched or lower radiation dose than their prior clinical CT scans performed using energy-integrating detector (EID) CT, and the potential clinical impact of PCD-CT was qualitatively evaluated. Phantom results showed water CT numbers within ±5 HU, and image uniformity measured between peripheral and central regions-of-interests to be within ±5 HU. For the UHR mode using a dedicated sharp kernel, the cut-off spatial frequency was 40 line-pairs cm −1 , which corresponds to a 125 μ m limiting in-plane spatial resolution. The full-width-at-half-maximum for the section sensitivity profile was 0.33 mm for the smallest slice thickness (0.2 mm) using the UHR mode. Material decomposition in a multi-energy CT phantom showed accurate material classification, with a root-mean-squared-error of 0.3 mg cc −1 for iodine concentrations (2–15 mg cc −1 ) and 14.2 mg cc −1 for hydroxyapatite concentrations (200 and 400 mg cc −1 ). The average percent error for CT numbers corresponding to the iodine concentrations in VMI (40–70 keV) was 2.75%. Patient PCD-CT images demonstrated better delineation of anatomy for chest and temporal bone exams performed with the UHR mode, which allowed the use of very sharp kernels not possible with EID-CT. VMI and virtual non-contrast images generated from a patient head CT angiography exam using the standard acquisition mode demonstrated the multi-energy capability of the PCD-CT system.
Association Between Graft Choice and 6-Year Outcomes of Revision Anterior Cruciate Ligament Reconstruction in the MARS Cohort
Group, MARS, Wright, Rick W. , Huston, Laura J. , Haas, Amanda K. , Pennings, Jacquelyn S. , Cooper, Daniel E. , Dunn, Warren R. , Lantz, Brett A., Stuart, Michael J., Albright, John P., Amendola, Annunziato , Andrish, Jack T. , Annunziata, Christopher C., Arciero, Robert A. , Bach, Bernard R. , Baker, Champ L., Bartolozzi, Arthur R. , Baumgarten, Keith M. , Bechler, Jeffery R., Berg, Jeffrey H., Bernas, Geoffrey A., Brockmeier, Stephen F. , Brophy, Robert H. , Bush‐Joseph, Charles A., Butler, J. Brad, Campbell, John D. , Carey, James L. , Carpenter, James E. , Cole, Brian J. , Cooper, Jonathan M. , Cox, Charles L. , Creighton, R. Alexander , Dahm, Diane L., Flanigan, David C. , Frederick, Robert W., Ganley, Theodore J. , Garofoli, Elizabeth A. , Gatt, Charles J. , Gecha, Steven R., Hame, Sharon L. , Hannafin, Jo A., Harner, Christopher D. , Harris, Norman Lindsay, Hechtman, Keith S., Hershman, Elliott B., Hoellrich, Rudolf G., Johnson, David C. , Johnson, Timothy S. , Kaeding, Christopher C. , Kamath, Ganesh V. , Klootwyk, Thomas E., Levy, Bruce A. , Benjamin, C. , Maiers, G. Peter, Marx, Robert G. , Matava, Matthew J. , Mathien, Gregory M., McCarty, Eric C. , McCormack, Robert G. , Miller, Bruce S. , Nissen, Carl W. , O’Neill, Daniel F., Parker, Richard D., Purnell, Mark L., Ramappa, Arun J. , Rauh, Michael A. , Rettig, Arthur C., Sekiya, Jon K., Slauterbeck, James R., Smith, Matthew V. , Spang, Jeffrey T. , Svoboda, LTC Steven J., Taft, Timothy N., Tenuta, Joachim J., Tingstad, Edwin M., Vidal, Armando F. , Viskontas, Darius G., White, Richard A., Wolcott, Michelle L., Wolf, Brian R. , York, James J. , Svoboda, Steven J. , Brophy, Robert H. , McCarty, Eric C , Group, MARS, Allen, Christina R. , DeBerardino, Thomas M. , Spindler, Kurt P , Stuart, Michael J., Campbell, John D., David, Tal S. , Giffin, J. Robert , Johnson, David C., Jones, Morgan H. , McAllister, David R. , Owens, Brett D. , Shea, Kevin G. , Sherman, Orrin H. , Williams, James S.

Mayo Clinic

The American Journal of Sports Medicine | July 14, 2021 | Volume: 49 | Issue: 10 | Pages: 2589-2598

10.1177/03635465211027170 | PMID 34260326 Get It

Background: Although graft choice may be limited in the revision setting based on previously used grafts, most surgeons believe that graft choice for anterior cruciate ligament (ACL) reconstruction is an important factor related to outcome. Hypothesis: In the ACL revision setting, there would be no difference between autograft and allograft in rerupture rate and patient-reported outcomes (PROs) at 6-year follow-up. Study Design: Cohort study; Level of evidence, 2. Methods: Patients who had revision surgery were identified and prospectively enrolled in this cohort study by 83 surgeons over 52 sites. Data collected included baseline characteristics, surgical technique and pathology, and a series of validated PRO measures. Patients were followed up at 6 years and asked to complete the identical set of PRO instruments. Incidence of additional surgery and reoperation because of graft failure were also recorded. Multivariable regression models were used to determine the predictors (risk factors) of PROs, graft rerupture, and reoperation at 6 years after revision surgery. Results: A total of 1234 patients including 716 (58%) men were enrolled. A total of 325 (26%) underwent revision using a bone-patellar tendon-bone (BTB) autograft; 251 (20%), soft tissue autograft; 289 (23%), BTB allograft; 302 (25%), soft tissue allograft; and 67 (5%), other graft. Questionnaires and telephone follow-up for subsequent surgery information were obtained for 809 (66%) patients, while telephone follow-up was only obtained for an additional 128 patients for the total follow-up on 949 (77%) patients. Graft choice was a significant predictor of 6-year Marx Activity Rating Scale scores ( P = .024). Specifically, patients who received a BTB autograft for revision reconstruction had higher activity levels than did patients who received a BTB allograft (odds ratio [OR], 1.92; 95% CI, 1.25-2.94). Graft rerupture was reported in 5.8% (55/949) of patients by their 6-year follow-up: 3.5% (16/455) of patients with autografts and 8.4% (37/441) of patients with allografts. Use of a BTB autograft for revision resulted in patients being 4.2 times less likely to sustain a subsequent graft rupture than if a BTB allograft were utilized ( P = .011; 95% CI, 1.56-11.27). No significant differences were found in graft rerupture rates between BTB autograft and soft tissue autografts ( P = .87) or between BTB autografts and soft tissue allografts ( P = .36). Use of an autograft was found to be a significant predictor of having fewer reoperations within 6 years compared with using an allograft ( P = .010; OR, 0.56; 95% CI, 0.36-0.87). Conclusion: BTB and soft tissue autografts had a decreased risk in graft rerupture compared with BTB allografts. BTB autografts were associated with higher activity level than were BTB allografts at 6 years after revision reconstruction. Surgeons and patients should consider this information when choosing a graft for revision ACL reconstruction.
MRI Evaluation of Patients Before and After Interventions for Benign Prostatic Hyperplasia: An Update
Diaz, Teresa A., Benson, Benjamin , Clinkenbeard, Alexander, Long, Jeremiah R. , Yano, Motoyo , Kawashima, Akira

Mayo Clinic

American Journal of Roentgenology | July 14, 2021 | Volume: 218 | Issue: 1 | Pages: 88-99

10.2214/ajr.21.26278 | PMID 34259037 Get It

Cost Conversations About Anticoagulation Between Patients With Atrial Fibrillation and Their Clinicians
Giblon, Rachel , Kunneman, Marlene, Lee, Alexander I., Hargraves, Ian , Sivly, Angela , Burnett, Bruce , Gorr, Haeshik, Roldan, Victor D. Torres , Spencer-Bonilla, Gabriella, Shah, Nilay D. , Brito, Juan P. , Investigators, Shared Decision Making for Atrial Fibrillation (SDM4AFib) Trial, Haffke, Alexander, Stier, Amy, Thota, Anjali, Simpson, Benjamin , Zeballos‐Palacios, Claudia , Vanmeter, Derek , Behnken, Emma , Ting, Henry H. , Anderson, Joel, Inselman, Jonathan , Muegge, Jule , Fleming, Kirsten, Olive, Marc, Vang, Miamoua, Ferrara, Michael J. , Wambua, Mike , Organick, Paige, Cabalka, Renee, Poplau, Sara , Abullarade, Carol, Keune, Shelly, Smith, Timothy D. , Barksdale, Bryan, Peters, Roma, Price, Memrie, Watson, Connie, Wolfe, Douglas A. , Haynes, Brian, Daniels, Paul R. , Jaeger, Thomas M. , Kamath, Celia C , Branda, Megan E. , Hargraves, Ian G, Sivly, Angela L, Torres Roldan, Victor D , Brito, Juan P , Kamath, Celia , Lee, Alexander I., Bellolio, Fernanda , Jackson, Elizabeth A. , Burnett, Bruce, Noseworthy, Peter A. , Montori, Víctor M. , Investigators, Shared Decision Making for Atrial Fibrillation (SDM4AFib) Trial, LeBlanc, Annie , Hess, Erik P. , Hamilton, James, Fleming, Kirsten, Linzer, Mark , Suzuki, Takeki , Harvey, Lisa Anne , Stephens, Shannon W. , Hickey, Theresa, Guyatt, Gordon , Tomlinson, George , Gersh, Bernard J. , McBane, Robert D.

Mayo Clinic

JAMA Network Open | July 13, 2021 | Volume: 4 | Issue: 7 | Pages: e2116009

10.1001/jamanetworkopen.2021.16009 | PMID 34255051 Get It

Persistent Hypertension and Left Ventricular Hypertrophy After Repair of Native Coarctation of Aorta in Adults
Egbe, Alexander C. , Miranda, William R. , Warnes, Carole A. , Bonnichsen, Crystal R. , Crestanello, Juan A. , Anderson, Jason H. , Connolly, Heidi M. , Bonnichsen, Crystal, Crestanello, Juan A , Anderson, Jason

Mayo Clinic

Hypertension | July 12, 2021 | Volume: 78 | Issue: 3 | Pages: 672-680

10.1161/hypertensionaha.121.17515 | PMID 34247510 Get It

The purpose of this study was to describe procedural outcomes, hemodynamic improvement, regression of left ventricular (LV) mass hypertrophy, and cardiovascular. The primary outcomes were procedural complications, reinterventions, and hemodynamic improvement after coarctation of aorta (COA) repair. The secondary outcomes were improvement in the severity of hypertension, regression of LV mass index, and incidence of cardiovascular events (atrial fibrillation, ventricular tachycardia, heart failure hospitalization, and cardiovascular death) after COA repair. Secondary outcomes were assessed only in patients with isolated COA who had clinical and imaging follow-up at 1 year and 3 years postintervention. Of 172 patients that underwent COA repair (surgical 161; transcatheter 11), there were no procedural deaths, and all patients had residual COA gradient <20 mm Hg. Of 128 patients that met criteria for secondary outcomes assessment, 39 (36%) had a reduction in the intensity of antihypertension therapy, and cardiovascular events occurred in 16 (13%) patients. There was no significant reduction in the overall prevalence of hypertension (stage 1 and stage 2) over time (78% versus 70% versus 73%, P =0.4 at baseline, 1 year and 3 years). Postintervention hypertension (both stage 1 and 2) were independent risk factors for suboptimal left ventricular mass index regression and cardiovascular events. Persistent hypertension was common after repair of native COA in adults and was associated with suboptimal left ventricular mass index regression and cardiovascular events. These results suggest that optimal blood pressure control with medical therapy after COA repair may result in improved clinical outcomes.
Characterization of a RAD51C -silenced high-grade serous ovarian cancer model during development of PARP inhibitor resistance
Hurley, Rachel M. , McGehee, Cordelia D. , Nesic, Ksenija , Weiskittel, Taylor M. , Kelly, Rebecca L. , Venkatachalam, Annapoorna , Hou, Xiaonan , Pathoulas, Nicholas M. , Meng, X. Wei, Kondrashova, Olga , Schneider, Paula A., Flatten, Karen S., Peterson, Kevin L. , Becker, Marc A., Southey, Melissa S, Harding, Thomas C., McNeish, Iain A. , Wagner, Jill M., Wakefield, Matthew J. , Scott, Clare L. , Hendrickson, Andrea E. Wahner , Karnitz, Larry M., Swisher, Elizabeth M. , Weroha, S. John , Lin, Kevin K. , Dobrovic, Alexander , Ross, Christian A, Haluska, Paul , Kaufmann, Scott H , McNeish, Iain A , Swisher, Elizabeth M , Wakefield, Matthew J , Scott, Clare L , Kondrashova, Olga , Correia, Cristina , Radke, Marc R. , Wong, Ee Ming , Lin, Kevin , Roß, Christian , Li, Hu , Kaufmann, Scott H.

Mayo Clinic

NAR Cancer | July 10, 2021 | Volume: 3 | Issue: 3 | Pages: No page available

10.1093/narcan/zcab028 | PMID 34316715 Get It

Abstract Acquired PARP inhibitor (PARPi) resistance in BRCA1- or BRCA2-mutant ovarian cancer often results from secondary mutations that restore expression of functional protein. RAD51C is a less commonly studied ovarian cancer susceptibility gene whose promoter is sometimes methylated, leading to homologous recombination (HR) deficiency and PARPi sensitivity. For this study, the PARPi-sensitive patient-derived ovarian cancer xenograft PH039, which lacks HR gene mutations but harbors RAD51C promoter methylation, was selected for PARPi resistance by cyclical niraparib treatment in vivo. PH039 acquired PARPi resistance by the third treatment cycle and grew through subsequent treatment with either niraparib or rucaparib. Transcriptional profiling throughout the course of resistance development showed widespread pathway level changes along with a marked increase in RAD51C mRNA, which reflected loss of RAD51C promoter methylation. Analysis of ovarian cancer samples from the ARIEL2 Part 1 clinical trial of rucaparib monotherapy likewise indicated an association between loss of RAD51C methylation prior to on-study biopsy and limited response. Interestingly, the PARPi resistant PH039 model remained platinum sensitive. Collectively, these results not only indicate that PARPi treatment pressure can reverse RAD51C methylation and restore RAD51C expression, but also provide a model for studying the clinical observation that PARPi and platinum sensitivity are sometimes dissociated.